Ticlopidine

CAS No. 55142-85-3

Ticlopidine( —— )

Catalog No. M17538 CAS No. 55142-85-3

Ticlopidine is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 30 In Stock
25MG 61 In Stock
50MG 90 In Stock
100MG 137 In Stock
200MG Get Quote In Stock
500MG 343 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ticlopidine
  • Note
    Research use only, not for human use.
  • Brief Description
    Ticlopidine is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor.
  • Description
    Ticlopidine is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor.(In Vitro):Ticlopidine exhibits activity against human CD39 with apparent Ki,app values of 14 μM.Ticlopidine inhibits recombinant human CD39 expressed in COS-7-cells with the Ki value of 127±12 μM.Growth rate is affected during the first days of culture, Ticlopidine (30 and 150 μM) reducing its effect in the following days.(In Vivo):Oral administration of Losartan with 10 mg/kg Ticlopidine significantly increases the AUC (by 65.0%), suggesting that Ticlopidine can effectively inhibit the metabolism of losartan in the intestine and/or liver.
  • In Vitro
    Ticlopidine exhibits activity against human CD39 with apparent Ki,app values of 14 μM.Ticlopidine inhibits recombinant human CD39 expressed in COS-7-cells with the Ki value of 127±12?μM.Growth rate is affected during the first days of culture, Ticlopidine (30 and 150 μM) reducing its effect in the following days. Cell Proliferation Assay Cell Line:Human endothelial cells Concentration:30 and 150 μM Incubation Time:2, 6; 10 days Result:Treated cells grow slower if compared with controls and this effect correlates with the concentration of Ticlopidine in the culture medium.
  • In Vivo
    Oral administration of Losartan with 10 mg/kg Ticlopidine significantly increases the AUC (by 65.0%), suggesting that Ticlopidine can effectively inhibit the metabolism of losartan in the intestine and/or liver. Animal Model:Male Sprague-Dawley rats (7-8 weeks old, weighing 270-300 g)Dosage:4 or 10 mg/kg Administration:Orally administered 30 min before oral administration of losartan.Result:The AUC and Cmax of Losartan after oral administration with Losartan and 10 mg/kg Ticlopidine were significantly greater (by 65.0% and 49.4%, respectively) than those of control rats.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    ADP
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    55142-85-3
  • Formula Weight
    263.78
  • Molecular Formula
    C14H14ClNS
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 100 mg/mL (379.09 mM)
  • SMILES
    C1CN(Cc2c1scc2)Cc1ccccc1Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Maffrand, JP (2012). Comptes Rendus Chimie. 15 (8): 737–743.
molnova catalog
related products
  • AZD8931 diFuMaric ac...

    AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth.

  • Mutated EGFR-IN-1

    Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.

  • Olmutinib

    Olmutinib is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorOlmutinib at 3 μM significantly reversed drug resistance mediated by ABCG2, but not by ABCB1 and ABCC1, by antagonizing the drug efflux function in ABCG2-overexpressing cells.?